



The HEARTS Clinical Pathway in the Region


TRINIDAD & TOBAGO




SAINT LUCIA



GUYANA




EL SALVADOR



BOLIVIA




MEXICO




ARGENTINA




BARBADOS




BRITISH VIRGIN ISLANDS



DOMINICA



PERU



COSTA RICA



CHILE




REP. DOMINICANA




Barbados

Hypertension Clinical Pathway



C TREATMENT PROTOCOL
START TREATMENT IMMEDIATELY AFTER CONFIRMING HYPERTENSION

Cardiovascular risk	All Hypertensives	HIGH-RISK Hypertensives
Blood Pressure TARGET <140/90 mmHg	✓	
Systolic Blood Pressure TARGET <130 mmHg		✓
ASPIRIN 81 mg/daily		✓
High-dose statins: ATORVASTATIN 80 mg/daily		✓
Moderate-dose statins: ATORVASTATIN 40 mg/daily		✓



Patients under control	Minimum 6-MONTH follow-up	Minimum 3-MONTH follow-up	Supply medicines for 3 MONTHS	Influenza	Vaccination Pneumococcus	COVID
All Hypertensives	✓		✓	✓	✓	✓
HIGH-RISK Hypertensives		✓	✓	✓	✓	✓


PAHO Pan American Health Organization **WHO** World Health Organization **HEARTS**

Barbados Ministry of Health and Wellness


ASSESS TREATMENT ADHERENCE AT EACH VISIT
TAKE ALL MEDICATIONS AT THE SAME TIME EVERY DAY

This protocol is NOT INDICATED in PREGNANCY


Trinidad & Tobago




Saint Lucia



Guyana



British Virgin Islands



Dominica

